BR112013000537A2 - composição aquosa contendo bromexina - Google Patents

composição aquosa contendo bromexina

Info

Publication number
BR112013000537A2
BR112013000537A2 BR112013000537A BR112013000537A BR112013000537A2 BR 112013000537 A2 BR112013000537 A2 BR 112013000537A2 BR 112013000537 A BR112013000537 A BR 112013000537A BR 112013000537 A BR112013000537 A BR 112013000537A BR 112013000537 A2 BR112013000537 A2 BR 112013000537A2
Authority
BR
Brazil
Prior art keywords
bromhexine
composition
containing aqueous
aqueous composition
aqueous
Prior art date
Application number
BR112013000537A
Other languages
English (en)
Other versions
BR112013000537B1 (pt
Inventor
Annette Zamponi
Bernd Plohmann
Uwe Scheuring
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063562&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013000537(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112013000537A2 publication Critical patent/BR112013000537A2/pt
Publication of BR112013000537B1 publication Critical patent/BR112013000537B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

composição aquosa contendo bromexina. a presente invenção refere-se a uma composição aquosa contendo bromexina, em que a composição apresenta uma quantidade de álcoois de açúcar de menos de 10 g com base em 100 ml da composição, bem como seu uso para a terapia secretolítica em doenças broncopulmonares agudas e crônicas.
BR112013000537-8A 2010-07-12 2011-07-07 Composição aquosa contendo bromexina e seu uso BR112013000537B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169236 2010-07-12
EP10169236.6 2010-07-12
PCT/EP2011/061527 WO2012007352A1 (de) 2010-07-12 2011-07-07 Wässrige zusammensetzung enthaltend bromhexin

Publications (2)

Publication Number Publication Date
BR112013000537A2 true BR112013000537A2 (pt) 2016-05-24
BR112013000537B1 BR112013000537B1 (pt) 2021-07-27

Family

ID=43063562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000537-8A BR112013000537B1 (pt) 2010-07-12 2011-07-07 Composição aquosa contendo bromexina e seu uso

Country Status (26)

Country Link
US (1) US9220693B2 (pt)
EP (1) EP2593094B1 (pt)
JP (1) JP5979763B2 (pt)
KR (1) KR101943812B1 (pt)
CN (1) CN103052384B (pt)
AR (1) AR082381A1 (pt)
AU (1) AU2011278451B2 (pt)
BR (1) BR112013000537B1 (pt)
CA (1) CA2803471C (pt)
CL (1) CL2012003625A1 (pt)
CO (1) CO6680609A2 (pt)
CY (1) CY1120079T1 (pt)
DK (1) DK2593094T3 (pt)
EA (1) EA025640B1 (pt)
EC (1) ECSP13012384A (pt)
ES (1) ES2661973T3 (pt)
HR (1) HRP20180396T1 (pt)
HU (1) HUE038399T2 (pt)
LT (1) LT2593094T (pt)
MX (1) MX337454B (pt)
PE (1) PE20131063A1 (pt)
PL (1) PL2593094T3 (pt)
PT (1) PT2593094T (pt)
SG (1) SG187016A1 (pt)
SI (1) SI2593094T1 (pt)
WO (1) WO2012007352A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013000537B1 (pt) 2010-07-12 2021-07-27 Boehringer Ingelheim International Gmbh Composição aquosa contendo bromexina e seu uso
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
JP6017249B2 (ja) * 2012-09-28 2016-10-26 小林製薬株式会社 経口投与用液体医薬組成物
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN103893116B (zh) * 2014-04-17 2015-12-09 河北仁合益康药业有限公司 一种盐酸溴己新口服液组合物
WO2015177147A1 (de) * 2014-05-23 2015-11-26 Boehringer Ingelheim International Gmbh Hustensaft enthaltend ambroxol hydrochlorid
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
CN111568861A (zh) * 2020-05-25 2020-08-25 河北科星药业有限公司 畜禽用盐酸溴己新口服液及其制备方法和应用
CN111714477B (zh) * 2020-07-23 2021-06-15 山东迅达康兽药有限公司 祛痰组合物及其口服液制备方法
CN113109463B (zh) * 2021-03-16 2022-11-25 浙江工业大学 一种复方氯丙那林溴己新胶囊中有关物质的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085784B2 (ja) 1987-06-17 1996-01-24 興和株式会社 シロツプ剤
US5624906A (en) * 1994-12-08 1997-04-29 Lever Brothers Company, Division Of Conopco, Inc. Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds
US6231890B1 (en) 1996-05-02 2001-05-15 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
JP3800437B2 (ja) 1996-07-24 2006-07-26 大正製薬株式会社 苦味が軽減された液剤
JPH10101581A (ja) 1996-09-26 1998-04-21 Taisho Pharmaceut Co Ltd 塩酸ブロムヘキシンの安定化製剤及び安定化方法
JPH10306038A (ja) 1997-05-07 1998-11-17 Taisho Pharmaceut Co Ltd ブロムヘキシン含有液剤
JP2000281562A (ja) * 1999-03-30 2000-10-10 Taisho Pharmaceut Co Ltd ゲル状組成物
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
EP1121940A1 (en) 2000-01-31 2001-08-08 New Pharma Research Sweden AB Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation
JP2002081562A (ja) 2000-09-05 2002-03-22 Kayaba Ind Co Ltd リリーフ弁
US6692725B2 (en) * 2001-02-19 2004-02-17 Daicel Chemical Industries, Ltd. Composition for oral care
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
JP5134802B2 (ja) 2005-09-29 2013-01-30 第一三共ヘルスケア株式会社 塩酸ブロムヘキシン含有量低下の防止方法
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
JP2008013542A (ja) * 2006-06-07 2008-01-24 Daiichi Sankyo Healthcare Co Ltd 去痰又は気道杯細胞過形成抑制のための医薬組成物
CN100409835C (zh) * 2007-04-06 2008-08-13 张嵩 含有溴己新盐的组合物及大容量注射剂和注射剂制备方法
KR101025498B1 (ko) * 2008-05-02 2011-03-31 (주)이엘티사이언스 염산브롬헥신 경구용 액제 복합조성물 및 그 제조방법
BR112013000537B1 (pt) 2010-07-12 2021-07-27 Boehringer Ingelheim International Gmbh Composição aquosa contendo bromexina e seu uso

Also Published As

Publication number Publication date
CO6680609A2 (es) 2013-05-31
KR101943812B1 (ko) 2019-01-31
AU2011278451B2 (en) 2014-11-27
HUE038399T2 (hu) 2018-10-29
EP2593094B1 (de) 2017-12-06
EA025640B1 (ru) 2017-01-30
CN103052384A (zh) 2013-04-17
JP5979763B2 (ja) 2016-08-31
JP2013531017A (ja) 2013-08-01
WO2012007352A1 (de) 2012-01-19
CL2012003625A1 (es) 2013-05-31
ECSP13012384A (es) 2013-03-28
EP2593094A1 (de) 2013-05-22
CA2803471C (en) 2019-01-15
CY1120079T1 (el) 2018-12-12
US20130267605A1 (en) 2013-10-10
SG187016A1 (en) 2013-02-28
AU2011278451A1 (en) 2013-01-24
LT2593094T (lt) 2018-03-26
PE20131063A1 (es) 2013-10-12
MX2013000417A (es) 2013-02-07
CN103052384B (zh) 2017-04-05
ES2661973T3 (es) 2018-04-04
HRP20180396T1 (hr) 2018-04-20
KR20130100091A (ko) 2013-09-09
SI2593094T1 (en) 2018-04-30
PL2593094T3 (pl) 2018-05-30
US9220693B2 (en) 2015-12-29
BR112013000537B1 (pt) 2021-07-27
PT2593094T (pt) 2018-03-12
MX337454B (es) 2016-03-07
AR082381A1 (es) 2012-12-05
CA2803471A1 (en) 2012-01-19
DK2593094T3 (en) 2018-03-12
EA201201659A1 (ru) 2013-06-28

Similar Documents

Publication Publication Date Title
BR112013000537A2 (pt) composição aquosa contendo bromexina
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
CU20140141A7 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas
CR20110163A (es) Uso de ditiina-tetracarboxamidas para combatir hongos fitopatógenos
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BR112012031616A2 (pt) forma cristalina do inibidor de benzilbenzeno sglt2
BR112015024926A2 (pt) composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
RS53783B1 (en) INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
BR112013020359B8 (pt) Colágeno gelificável e meios para a sua provisão
BR112014029874A8 (pt) composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica
BR112014016890A8 (pt) composição para controle de doenças de plantas
ES2446215R2 (es) Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.